MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma

Jiwei Zhang¹, Zehua Bian¹, Jialiang Zhou², Mingxu Song¹, Zhihui Liu¹, Yuyang Feng¹, Li Zhe³, Binbin Zhang¹, Yuan Yin¹, Zhaohui Huang¹

¹ Wuxi Oncology Institute, The Affiliated Hospital of Jiangnan University, Wuxi 214062, China
² Department of Radiation Oncology, The Affiliated Hospital of Jiangnan University, Wuxi 214062, China
³ Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China

Correspondence: hzhwxsy@126.com (Z. Huang)
Received May 12, 2015 Accepted June 11, 2015

ABSTRACT
MicroRNAs (miRNAs) are a type of small non-coding RNAs that are often play important roles in carcinogenesis, but the carcinogenic mechanism of miRNAs is still unclear. This study will investigate the function and the mechanism of miR-638 in carcinoma (GC). The expression of miR-638 in GC and the DNA copy number of miR-638 were detected by real-time PCR. The effect of miR-638 on cell proliferation was measured by counting kit-8 assay. Different assays, including bioinformatics algorithms (TargetScan and miRanda), luciferase report assay and Western blotting, were used to identify the target gene of miR-638 in GC. The expression of miR-638 target gene in clinical CRC tissues was also validated by immunohistochemical assay. From this research, we found that miR-638 was downregulated in GC tissues compared with corresponding noncancerous tissues (NCTs), and the DNA copy number of miR-638 was lower in GC than NCTs, which may induce the corresponding downregulation of miR-638 in GC. Ectopic expression of miR-638 inhibited GC cell growth in vitro. Subsequently, we identified that PLD1 is the target gene of miR-638 in GC, and silencing PLD1 expression phenocopied the inhibitory effect of miR-638 on GC cell proliferation. Furthermore, we observed that PLD1 was overexpressed in GC tissues, and high expression of PLD1 in GC predicted poor overall survival. In summary, we revealed that miR-638 functions as a tumor suppressor in GC through inhibiting PLD1.

KEYWORDS gastric cancer, miR-638, cell proliferation, PLD1

INTRODUCTION
MicroRNAs (miRNAs) are endogenous 19–25 nt RNAs that play important gene-regulatory roles in animals and plants through binding to the 3′untranslated region (3′UTR) of target mRNAs, and they can take part in cell development, differentiation and proliferation (Bartel, 2009; Sreekumar et al., 2011). Studies have shown that miRNAs played important roles in the progression of various cancers over the past few years, including gastric carcinoma (GC) (Esquela-Kerscher and Slack, 2006; Cho, 2010). However, the biological functions and molecular mechanisms of many miRNAs in GC remain unclear.

GC is one of the most common human malignant cancers worldwide, about one million new GC cases and 723,000 deaths are estimated to have occurred in 2012, accounting for 8% of the total cases and 10% of total deaths (http://globocan.iarc.fr). Over 70% of new cases and deaths occur in developing countries (Jemal et al., 2011). Many miRNAs were reported to be associated with GC development in the past decade, including miR-146a (Yao et al., 2013), miR-204-5p (Zhang et al., 2015), miR-486 (Oh et al., 2011), miR-192 (Jin et al., 2011), miR-215 (Jin et al., 2011),
miR-34b/c (Suzuki et al., 2010), miR-29a (Cui et al., 2011), miR-409-3p (Li et al., 2012a), and miR-296-5p (Li et al., 2014). These reports indicate that miRNAs play important roles in CRC development and progression, providing new avenues for GC diagnostic and therapeutic application (Ma et al., 2012). Although many research teams have developed new GC therapies recently, further deeply investigations on molecular mechanisms underlying GC carcinogenesis are urgently needed to improve GC diagnosis and therapy.

We previously identified some differentially expressed miRNAs that could serve as prognostic and diagnostic factors for colorectal cancer (CRC) and determined that some of these deregulated miRNAs appeared to be highly related to the tumor prognosis (Huang et al., 2010; Huang et al., 2012; Song et al., 2014; Yin et al., 2014; Zhang et al., 2014; Zhang et al., 2015). Among them, we found that miR-638 is also down-regulated in GC as it in CRC. In the current study, we comprehensively investigate the biological functions and underlying molecular mechanism of miR-638 in GC carcinogenesis. The enhanced expression of miR-638 is also down-regulated in GC as it in CRC. In the current study, we comprehensively investigate the biological functions and underlying molecular mechanism of miR-638 in GC carcinogenesis. The enhanced expression of miR-638 can inhibit cell proliferation in vitro. Furthermore, phospholipase D1 (PLD1), a putative cell apoptosis suppressor in GC, is characterized as a direct and functional target of miR-638, which provides a possible regulation pathway for PLD1 and a candidate target forthediagnostics and treatment of GC.

RESULTS

Expression of miR-638 is down-regulated in GC tissues

As our previous research has found that miR-638 is down-regulated in CRC (Huang et al., 2011; Zhang et al., 2014), we intend to clarify whether miR-638 is down-regulated in GC. To validate this issue, we examined the mature miR-638 expression level in 64 GC tissues using qRT-PCR. The result showed that the miR-638 expression was down-regulated in 36 of 64 (56.25%) GC tissues when compared to the corresponding NCTs (P < 0.001, Fig. 1A and 1B). Because the deletion of DNA sequence coding for miRNAs can result in the downregulation of corresponding miRNAs, so we checked the pri-miR-638 copy number by qPCR in 24 pairs of GC tissues and NCTs to determine the reason of miR-638 downregulation in GC. Interestingly, we found that pri-miR-638 copy number was lower in GC tissues compared with their NCT counterparts (P < 0.05, Fig. 1C), suggesting that down-regulation of miR-638 in GC was modulated by the loss of DNA copy number.

However, we did not observe significant association between miR-638 expression in GC tissues and overall survival (OS) of GC patients (P > 0.05, Fig. 1D). In addition, miR-638 expression was not significantly associated with gender, age, tumor location, size, stage, and grading (P > 0.05).

MiiR-638 represses GC cell proliferation in vitro

The down-regulation of miR-638 in GC suggests that it may involve in GC tumorigenesis. Cell proliferation assay revealed that miR-638 overexpression significantly reduced the growth rates of MKN-45 and SGC-7901 cells (P < 0.05, Fig. 2A), and colony formation assay confirmed that miR-638 inhibited the proliferation function of GC cells (P < 0.05, Fig. 2C). In contrast, silencing miR-638 expression significantly promoted the growth of MKN-45 and SGC-7901 cells (P < 0.05, Fig. 2B). In conclusion, all these data show that miR-638 has the function of growth inhibitory.

MiiR-638 directly binds to the 3'UTR of PLD1

To elucidate the mechanism underlying miR-638-mediated suppression of cell proliferation, we used two computer-aided algorithms, TargetScan and miRanda, to search for potential target genes of miR-638. Among the 12 potential tumor-related targets, 7 genes were significantly down-regulated in MKN-45 and SGC-7901 cells transfected with miR-638 and were considered to be the candidate targets of miR-638 (Fig. 3A). Based on these data and our previous results in CRC (Zhang et al., 2014), we focused on PLD1 and DEF6 for the subsequent analysis. The effects of the two candidate targets on cell proliferation were performed on MKN-45 and SGC-7901 cells using PLD1- or DEF6-specific siRNA. The results indicated that silencing PLD1 expression significantly decreased cell proliferation in both of MKN-45 and SGC-7901, which was not observed in the GC cells with silenced DEF6 expression (Fig. 3B). Taken together, these results suggest that PLD1 is a potential target gene of miR-638 in GC.

To further verify that PLD1 is a direct target gene of miR-638 in human GC, we generated a luciferase reporter plasmid which carried the mutated binding site of miR-638 in the PLD1 3'UTR, (Fig. 3C), and found that miR-638 had no effect on the activity of luciferase with mutant 3’UTR of PLD1 in HEK-293T, MKN-45, and SGC-7901 (Fig. 3D), suggesting the sequence-specific inhibiting of miR-638 on the PLD1 expression. In line with these results, the endogenous PLD1 protein level was also decreased in miR-638-overexpression GC cells and could be restored in miR-683-depleted GC cells (Fig. 3E).

MiiR-638 represses proliferation through directly targeting PLD1 in human GC cells

To further examine whether PLD1 is a direct functional target of miR-638 in GC cells, we performed a series of functional restoration assays. As shown in Fig. 4A, the proliferation of MKN-45 and SGC-7901 cells transfected with si-PLD1 were significantly decreased (Fig. 4A). Also, in miR-638 transfection group, the proliferation ability of GC cells were decreased, whereas anti-miR-638 could not restore cell proliferation in PLD1-knockdown GC cells (Fig. 4B).

© The Author(s) 2015. This article is published with open access at Springerlink.com and journal.hep.com.cn 681
Furthermore, we revealed that PLD1 over-expression could significantly promote cell proliferation, which could not be repressed by either the exogenous or endogenous over-expression of miR-638 (Fig. 4C–E). Taken together, all of these results proved that miR-638 inhibits cell proliferation via directly targeting PLD1.

PLD1 levels are negatively correlated with miR-638 expression and GC prognosis

To further evaluate the relationship between miR-638 and PLD1 in human GC, PLD1 expression levels in GC tissues and paired NCTs were examined by IHC assay. As Fig. 5A and 5B showed, PLD1 protein expression in GC was upregulated in 71/120 cases compared with paired NCTs, and was inversely correlated with the miR-638 levels ($P < 0.05$, Fig. 5C), which suggested that the increased PLD1 expression in GC was caused by miR-638 under-expression. Survival analyses revealed that increased PLD1 protein levels (score 2 or 3) were associated with shorter survival time ($P = 0.0272$, Fig. 5D). After adjusting from tumor size, grading, and stage, multivariate analyses showed that PLD1 expression was an independent risk factor for survival (Table S1). Patients with higher PLD1 expression presented a higher risk of death ($HR = 3.3049$, 95% CI = 1.213–6.375, $P < 0.05$) (Tables S1 and S2). Taken together, these data suggest that PLD1 appears to be a new prognostic factor for GC.

DISCUSSION

Nowadays, more than 2,000 miRNAs have been identified in human, as an important gene regulated factor, it has been identified as a key regulation factor for the tumor cell proliferation, migration, and invasion. Down-regulation of miR-638 was first identified in human non-small-cell lung cancer (NSCLC) tissues (Li et al., 2012b). Our previous work showed that miR-638 was downregulated in human CRC, and loss of miR-638 promotes CRC cell proliferation (Zhang et al., 2014). Other groups found that the loss of miR-638 could promote cell invasion and a mesenchymal-like transition in CRC cells (Ma et al., 2014), and downregulation of miR-638 promotes cell invasion and proliferation in NSCLS.
These data suggest a key role of miR-638 in human tumorigenesis.

GC is the second leading cause of global cancer mortality and most of GC patients are diagnosed with advanced-stage diseases (Cidon et al., 2013). As miR-638 had been verified to be down-regulated in CRC, we want to clarify whether it is also abnormal in human GC. We checked the expression of miR-638 in 64 paired of GC tissues and NCTs, and observed significantly down-regulation of miR-638 in GC, which was consistent with a previous report (Shrestha et al., 2014).

The miR-638 gene is an intronic miRNA located on the first intron of DNM2. Our previous study revealed promoter methylation is a potential mechanism accounting for the down-regulation of the miR-638 in CRC. Copy number variants (CNV) are the other notable structural variations in the human genome that influence gene expression. Several studies have examined the CNVs of miRNAs and revealed their potential consequences (Ding et al., 2010; Wang et al., 2014). We observed that the copy numbers of pri-miR-638 were decreased in GC compared with NCT samples, suggesting that it account for, at least partly, the downregulation of miR-638 in GC. However, for the relative small case number in this study, these findings should be confirmed in an enlarged GC cohort in the future study.

In this study, we found that loss of miR-638 repressed cell proliferation and colony formation in GC via its direct target, PLD1. In addition to affecting proliferation, the role of miR-638 in metastasis is another important aspect that must be considered in future researches. PLD1 is an enzyme that can convert phospholipid to phosphatidic acid (PA), and two isoforms of phosphatidylcholine-specific PLD, PLD1 and PLD2 have been identified. PLD is upregulated at protein

(Xia et al., 2014). These data suggest a key role of miR-638 in human tumorigenesis.

GC is the second leading cause of global cancer mortality and most of GC patients are diagnosed with advanced-stage diseases (Cidon et al., 2013). As miR-638 had been verified to be down-regulated in CRC, we want to clarify whether it is also abnormal in human GC. We checked the expression of miR-638 in 64 paired of GC tissues and NCTs, and observed significantly down-regulation of miR-638 in GC, which was consistent with a previous report (Shrestha et al., 2014).

The miR-638 gene is an intronic miRNA located on the first intron of DNM2. Our previous study revealed promoter methylation is a potential mechanism accounting for the down-regulation of the miR-638 in CRC. Copy number variants (CNV) are the other notable structural variations in the human genome that influence gene expression. Several studies have examined the CNVs of miRNAs and revealed their potential consequences (Ding et al., 2010; Wang et al., 2014). We observed that the copy numbers of pri-miR-638 were decreased in GC compared with NCT samples, suggesting that it account for, at least partly, the downregulation of miR-638 in GC. However, for the relative small case number in this study, these findings should be confirmed in an enlarged GC cohort in the future study.

In this study, we found that loss of miR-638 repressed cell proliferation and colony formation in GC via its direct target, PLD1. In addition to affecting proliferation, the role of miR-638 in metastasis is another important aspect that must be considered in future researches. PLD1 is an enzyme that can convert phospholipid to phosphatidic acid (PA), and two isoforms of phosphatidylcholine-specific PLD, PLD1 and PLD2 have been identified. PLD is upregulated at protein

(Xia et al., 2014). These data suggest a key role of miR-638 in human tumorigenesis.

GC is the second leading cause of global cancer mortality and most of GC patients are diagnosed with advanced-stage diseases (Cidon et al., 2013). As miR-638 had been verified to be down-regulated in CRC, we want to clarify whether it is also abnormal in human GC. We checked the expression of miR-638 in 64 paired of GC tissues and NCTs, and observed significantly down-regulation of miR-638 in GC, which was consistent with a previous report (Shrestha et al., 2014).

The miR-638 gene is an intronic miRNA located on the first intron of DNM2. Our previous study revealed promoter methylation is a potential mechanism accounting for the down-regulation of the miR-638 in CRC. Copy number variants (CNV) are the other notable structural variations in the human genome that influence gene expression. Several studies have examined the CNVs of miRNAs and revealed their potential consequences (Ding et al., 2010; Wang et al., 2014). We observed that the copy numbers of pri-miR-638 were decreased in GC compared with NCT samples, suggesting that it account for, at least partly, the downregulation of miR-638 in GC. However, for the relative small case number in this study, these findings should be confirmed in an enlarged GC cohort in the future study.

In this study, we found that loss of miR-638 repressed cell proliferation and colony formation in GC via its direct target, PLD1. In addition to affecting proliferation, the role of miR-638 in metastasis is another important aspect that must be considered in future researches. PLD1 is an enzyme that can convert phospholipid to phosphatidic acid (PA), and two isoforms of phosphatidylcholine-specific PLD, PLD1 and PLD2 have been identified. PLD is upregulated at protein

(Xia et al., 2014). These data suggest a key role of miR-638 in human tumorigenesis.

GC is the second leading cause of global cancer mortality and most of GC patients are diagnosed with advanced-stage diseases (Cidon et al., 2013). As miR-638 had been verified to be down-regulated in CRC, we want to clarify whether it is also abnormal in human GC. We checked the expression of miR-638 in 64 paired of GC tissues and NCTs, and observed significantly down-regulation of miR-638 in GC, which was consistent with a previous report (Shrestha et al., 2014).

The miR-638 gene is an intronic miRNA located on the first intron of DNM2. Our previous study revealed promoter methylation is a potential mechanism accounting for the down-regulation of the miR-638 in CRC. Copy number variants (CNV) are the other notable structural variations in the human genome that influence gene expression. Several studies have examined the CNVs of miRNAs and revealed their potential consequences (Ding et al., 2010; Wang et al., 2014). We observed that the copy numbers of pri-miR-638 were decreased in GC compared with NCT samples, suggesting that it account for, at least partly, the downregulation of miR-638 in GC. However, for the relative small case number in this study, these findings should be confirmed in an enlarged GC cohort in the future study.

In this study, we found that loss of miR-638 repressed cell proliferation and colony formation in GC via its direct target, PLD1. In addition to affecting proliferation, the role of miR-638 in metastasis is another important aspect that must be considered in future researches. PLD1 is an enzyme that can convert phospholipid to phosphatidic acid (PA), and two isoforms of phosphatidylcholine-specific PLD, PLD1 and PLD2 have been identified. PLD is upregulated at protein

(Xia et al., 2014). These data suggest a key role of miR-638 in human tumorigenesis.

GC is the second leading cause of global cancer mortality and most of GC patients are diagnosed with advanced-stage diseases (Cidon et al., 2013). As miR-638 had been verified to be down-regulated in CRC, we want to clarify whether it is also abnormal in human GC. We checked the expression of miR-638 in 64 paired of GC tissues and NCTs, and observed significantly down-regulation of miR-638 in GC, which was consistent with a previous report (Shrestha et al., 2014).

The miR-638 gene is an intronic miRNA located on the first intron of DNM2. Our previous study revealed promoter methylation is a potential mechanism accounting for the down-regulation of the miR-638 in CRC. Copy number variants (CNV) are the other notable structural variations in the human genome that influence gene expression. Several studies have examined the CNVs of miRNAs and revealed their potential consequences (Ding et al., 2010; Wang et al., 2014). We observed that the copy numbers of pri-miR-638 were decreased in GC compared with NCT samples, suggesting that it account for, at least partly, the downregulation of miR-638 in GC. However, for the relative small case number in this study, these findings should be confirmed in an enlarged GC cohort in the future study.

In this study, we found that loss of miR-638 repressed cell proliferation and colony formation in GC via its direct target, PLD1. In addition to affecting proliferation, the role of miR-638 in metastasis is another important aspect that must be considered in future researches. PLD1 is an enzyme that can convert phospholipid to phosphatidic acid (PA), and two isoforms of phosphatidylcholine-specific PLD, PLD1 and PLD2 have been identified. PLD is upregulated at protein
and/or activity levels in various cancers (Zhang and Frohman, 2014). Our present study showed that PLD1 is overexpressed in GC tissues compared with adjacent NCTs, and PLD1 appears to be a new prognostic factor for GC. Although upregulation of PLD1 plays an important role in increasing cell proliferation, the molecular mechanisms mediating PLD1 expression in GC cells are still unclear. The expression of PLD1 was reported to be induced in GC cells by infecting with cagA-positive H. pylori (Kang et al., 2013). We reported here that loss of miR-638 caused overexpression of PLD1 in GC cells. This mechanism explicated the reason of PLD1 overexpression in GC cells in a post-transcriptional regulation level. The present study showed that miR-638 is frequently down-regulated in GC, which partly attributed to the copy number of miR-638 locus; and miR-638 functions as a new repressor of GC cell proliferation. In addition, PLD1 identified as functional target of miR-638 in this study, was upregulated in GC and was closely related to the prognosis of GC patients. These results suggest that miR-638/PLD1 signalling could be a useful marker in GC and potential therapeutic targets for the treatment of GC patients.

**MATERIALS AND METHODS**

**Cell lines and clinical samples**

HEK-293T cell line was purchased from the American Type Culture Collection (ATCC), and human GC cell lines (MKN-45 and SGC-7901) were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. The human GC cell lines MKN-45 and SGC-7901 were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic (Life Technologies).
MiR-638 through PLD1 inhibits cell proliferation in GC

7901) were purchased from Shanghai Meixuan. All of the media (HyClone, USA) were supplemented with 10% fetal bovine serum (FBS) (Gibco, USA). SGC-7901, MKN45, and HEK-293T cells were cultured in DMEM.

A total of 64 pairs of human primary GC tissues and their adjacent NCTs were collected between 2008 and 2012 at the Affiliated Hospital of Jiangnan University. The tissue samples were immediately snap-frozen in liquid nitrogen and were histologically confirmed. All of the human materials were obtained with informed consent, and this project was approved by the Clinical Research Ethics Committee of Affiliated Hospital of Jiangnan University.

DNA and RNA isolation

Genomic DNA was isolated using the General AllgGen Kit (Cwbio, China) according to the manufacturer’s protocol. Total RNA was extracted using RNAiso reagent (Takara, Japan). The concentrations of DNA and RNA were determined using NanoDrop 2000 (Thermo, USA).

Complementary DNA (cDNA) was synthesized using the PrimeScript RT reagent kit (TaKaRa, Japan). QRT-PCR analyses were conducted to quantitate the relative mRNA expression using SYBR Premix Ex Taq (TaKaRa), with β-actin as an internal control. Stem-loop qRT-PCR assays using TaqMan miRNA probes (Applied Biosystems, USA) were performed to quantify the levels of the mature miRNAs. The reactions were incubated in 96- or 384-well optical plates at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. After the reactions, the cycle threshold (Ct) data were determined using default threshold settings, and the mean Ct was determined from the duplicate PCRs. A comparative ΔCt method was used to compare each condition with the controls, and the values are expressed as 2−ΔCt. The relative levels of miRNAs were normalized to the levels of U6, a ubiquitously expressed small nuclear RNA. The relative DNA copy numbers were determined as described previously (Wang et al., 2002).

Figure 4. MiR-638 repressed GC cell proliferation by inhibiting PLD1. (A) PLD1 knockdown repressed MKN-45 and SGC-7901 cells growth, whereas upregulation of miR-638 in PLD1-depleted cells did not repress cell proliferation further. (B) MiR-638 silencing promoted cell growth, but did not promote cell proliferation in PLD1-depleted GC cells. (C) The upregulation of PLD1 ORF markedly promoted cell growth and abrogated miR-638-induced cell growth inhibition in MKN-45 and SGC-7901 cells. (D) MiR-638 overexpression promoted apoptosis. PLD1 overexpression repressed cell apoptosis and decreased the percentage of apoptotic cells after miR-638 overexpression. (E) The protein level of PLD1 was measured by Western blotting. Significant differences are indicated with * (*P < 0.05; **P < 0.01).
Plasmid and siRNA

The miR-638 lentivirus expression vector pWPXL-miR-638 was constructed as described (Zhang et al., 2014). The 3′ UTRs of potential miR-638 target genes were amplified from genomic DNA using PrimerSTAR Premix (TaKaRa). The amplified 3′ UTRs were then cloned into the region directly downstream of a CMV promoter-driven firefly luciferase cassette in a pcDNA3.0 vector (p-Luc). The mutant 3′-UTR of PLD1, which carried the mutated sequence in the complementary site for the seed region of miR-638, was constructed based on the p-Luc-PLD1 3′-UTR-WT plasmid by overlap-extension PCR. The open reading frame (ORF) of PLD1 was amplified and cloned into pWPXL. Duplex siRNAs were purchased from GenePharma (Shanghai, China). The anti-miRNA inhibitors (GenePharma, China) are single-stranded nucleic acids chemically modified to specifically bind to and inhibit endogenous miRNA molecules.

Lentivirus production and transduction

Virus packaging was performed in HEK 293T cells after co-transfection of pWPXL-638 or pWPXL-PLD1 with the packaging plasmid psPAX2 and envelope plasmid pMD2.G using Lipofectamine 2000 (Invitrogen). Viruses were harvested 48 h after transfection, and viral titers were determined. Target cells (1 × 10^5), including MKN-45 and SGC-7901 cells, were infected with 1 × 10^6 recombinant lentivirus-transducing units in the presence of 6 μg/mL polybrene (Sigma, MO).

Cell proliferation assay and colony formation assay

As the cell proliferation was quantified using the Cell Counting Kit-8 (CCK8; Dojindo Laboratories, Japan) according to the manufacturer’s instructions. For the colony formation assays, 1000 cells of MKN-45 and 1500 cells of SGC-7901 cells were plated into each well of 6-well plates and incubated in medium containing 10% FBS for 2 weeks. The colonies were fixed with methanol and stained with 0.1% crystal violet in 20% methanol for 20 min. The number of colonies containing more than about 30 cells was counted using an inverted microscope.

Luciferase assay

Approximately 5,000 HEK-293T cells or 10,000 GC cells (MKN-45 and SGC-7901) per well were plated into 96-well plates and were
The results were presented as the mean ± standard error of the mean. PLD1 protein score was estimated based on the overall staining strength. Immunohistochemical staining was performed on 4 μm thick sections of formalin-fixed and paraffin-embedded tissues using a mouse anti-PLD1 monoclonal antibody (SIGMA, USA) diluted 1:400 at 4°C overnight. The subsequent steps were performed using the EnVision™ FLEX High pH visualisation system according to the manufacturer's instructions (DAKO, Denmark). The PLD1 protein score was estimated based on the overall staining strength.

Statistical analysis

The results were presented as the mean ± standard error of the mean (SEM). The data were subjected to two-tailed Student’s t test (P < 0.05) unless otherwise specified (χ² test or Spearman’s correlation). Cox proportional hazards regression analysis was used to estimate the hazard ratios (HRs) and the 95% confidence intervals (CIs). A value of P < 0.05 was considered to be statistically significant. The SPSS 16.0 package (IBM, USA) was used for the statistical analyses.

ACKNOWLEDGEMENTS

This work was supported by Grants from the National Natural Science Foundation of China (Grant Nos. 81000867, 81272299, 81301784, and 81301920) and Medical Key Professionals Program of Jiangsu Province (RC2011031).

ABBREVIATIONS

3’UTR, 3’untranslated region; GC, gastric carcinoma; miRNAs, microRNAs; PLD1, phospholipase D1.

COMPLIANCE WITH ETHICS GUIDELINES

Jiwei Zhang, Zehua Bian, Jialiang Zhou, Mingxu Song, Zhihui Liu, Yuyang Feng, Li Zhe, Binbin Zhang, Yuan Yin, and Zhaohui Huang declare that he has no conflict of interest.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Wuxi Oncology Institute, The Affiliated Hospital of Jiangnan University). Informed consent was obtained from all patients for being included in the study.

OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233

Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42:1273–1281

Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T (2013) Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers 5:64–91

Cui Y, Su WY, Xing J, Wang YC, Wang P, Chen XY, Shen ZY, Cao H, Lu YY, Fang JY (2011) MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p21 in human gastric cancer. PLoS One 6:e26587

Ding J, Huang S, Wu S, Zhao Y, Liang L, Yan M, Ge C, Yao J, Chen T, Wan D et al (2010) Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol 12:390–399

Esquela-Kerscher A, Slack FJ (2006) Oncomirs—miRNAs with a role in cancer. Nat Rev Cancer 6:259–269

Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127:118–126

Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, Sheng W, He X, Du X (2011) MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 71:2582–2589

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Moli Y, Olaru AV, Yang J, David S, Hamilton JP et al (2011) MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 30:1577–1585

Kang DW, Hwang WC, Park MH, Ko GH, Ha WS, Kim KS, Lee YC, Choi KY, Min DS (2013) Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NFkappaB and suppresses invasion of gastric cancer cells. Oncogene 32:3531–3542

Li C, Nie H, Wang M, Su L, Li J, Yu B, Wei M, Ju J, Yu Y, Yan M et al (2012a) MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer Lett 320:189–197

Li D, Wang Q, Liu C, Duan H, Zeng X, Zhang B, Li X, Zhao J, Tang S, Li Z et al (2012b) Aberrant expression of miR-638 contributes...
to benzo(a)pyrene-induced human cell transformation. Toxicol Sci 125:382–391
Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li H, Zhou L, Han YN, Wu KC, Nie YZ et al (2014) MicroRNA-296-5p increases proliferation in gastric cancer through repression of caudal-related homeobox 1. Oncogene 33:783–793
Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H (2012) Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer 130:2077–2087
Ma K, Pan X, Fan P, He Y, Gu J, Wang W, Zhang T, Li Z, Luo X (2014) Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells. Mol Cancer 13:118
Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, Rha SY et al (2011) Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res 17:2657–2667
Shrestha S, Hsu SD, Huang WY, Huang HY, Chen W, Weng SL, Huang HD (2014) A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med 3(4):878–888
Song M, Yin Y, Zhang J, Zhang B, Bian Z, Quan C, Zhou L, Hu Y, Wang Q, Ni S et al (2014) MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. Protein Cell 5:851–861
Sreekumar R, Sayan BS, Miencezami AH, Sayan AE (2011) MicroRNA control of invasion and metastasis pathways. Front Genet 2:58
Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T et al (2010) Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 31:2066–2073
Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, Velculescu VE (2002) Digital karyotyping. Proc Natl Acad Sci USA 99:16156–16161
Wang Q, Huang Z, Guo W, Ni S, Xiao X, Wang L, Huang D, Tan C, Xu Q, Zha R et al (2014) microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma. Clin Cancer Res 20:1146–1157
Xia Y, Wu Y, Liu B, Wang P, Chen Y (2014) Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC. FEBS Lett 588:2238–2245
Yao Q, Cao Z, Tu C, Zhao Y, Liu H, Zhang S (2013) MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2. Cancer Lett 335:219–224
Yin Y, Zhang B, Wang W, Fei B, Quan C, Zhang J, Song M, Bian Z, Wang Q, Ni S et al (2014) miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res 20:6187–6199
Zhang Y, Frohman MA (2014) Cellular and physiological roles for phospholipase D1 in cancer. J Biol Chem 289:22567–22574
Zhang J, Fei B, Wang Q, Song M, Yin Y, Zhang B, Ni S, Guo W, Bian Z, Quan C et al (2014) MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. Oncotarget 5:12083–12096
Zhang B, Yin Y, Hu Y, Zhang J, Bian Z, Song M, Hua D, Huang Z (2015) MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A. Med Oncol 32:331